Filing Flows › Hyperfine (HYPR) › Recalls, complaints & regulation
Hyperfine (HYPR): clinical trials
Hyperfine (HYPR) beyond its filings: 1 active clinical trial.
Hyperfine's latest quarter
Hyperfine, Q2 2026: revenue $3.9M (+45% year over year), operating margin -216.9%, net loss $9.3M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Hyperfine have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.